NCT05839912

Excision of Lymph Node Trial (EXCILYNT) (Mel69)

Lymph Node Excision (LNEx) for Patients With Stage III Melanoma With One Clinically Positive Node: Excision of Lymph Node Trial [EXCILYNT]

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 66 (estimated)
• Sponsor: Craig L Slingluff, Jr · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to find out if removing only the cancerous lymph node (known as a lymph node excision) is effective at preventing cancer from coming back in the same area of the lymph node excision. The study team is also trying to find out the side effects of this type of surgery and how much the surgery impacts quality of life. In order to be eligible for this study, participants must have been diagnosed with metastatic melanoma and have one detected cancerous lymph node by imaging (CT/PET scan) or clinical examination, and are a candidate for lymph node excision.

Conditions

• Melanoma

Interventions

Type	Name	Description
PROCEDURE	Excision of clinically detected lymph node metastasis before any systemic therapy	Surgical intervention to remove the clinically detected lymph node metastasis after which physician choice adjuvant systemic therapy is permitted
PROCEDURE	Excision of clinically detected lymph node metastasis after neoadjuvant systemic therapy	Surgical intervention to remove the clinically detected lymph node metastasis after physician choice neo adjuvant systemic therapy. Physician choice adjuvant therapy is allowed after surgery

Timeline

• Start date: 2023-09-06
• Primary completion: 2028-09-01
• Completion: 2028-09-01
• First posted: 2023-05-03
• Last updated: 2025-09-17

Locations

7 sites across 1 country: United States